My current research focuses are (1) to better understand the tumor microenvironment and heterogeneity of osteosarcoma using single cell RNA sequencing and spatial transcriptomic analyses, and (2) to investigate alternative splicing events in osteosarcoma using hybrid RNA sequencing. The goal is to identify new biomarkers predicting treatment response, metastasis and survival and new therapeutic target for new treatment development.
In my previous positions, I led the development of medium-throughput in vitro functional platform testing the somatic mutations and fusions identified from cancer patients using 2 cell models, Ba/F3 and MCF10A and tested over 1,600 mutations and fusions, including allelic series of oncogenes PIK3CA, EGFR and BRAF. In addition, I worked proteomic analysis of lung adenocarcinoma, Head and neck squamous cell carcinoma as well as pan-cancers under The Cancer Genome Atlas (TCGA) program.